Market Size –
The biologics contract development market size has grown rapidly in recent years. It will grow from <b>$6.94 billion in 2023 to $7.7 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. </b> The growth in the historic period can be attributed to biologics market growth, rise in biopharmaceuticals, complexity of biologics, patent expirations, cost efficiency.
The biologics contract development market size is expected to see rapid growth in the next few years. It will grow to <b>$11.68 billion in 2028 at a compound annual growth rate (CAGR) of 11.0%. </b> The growth in the forecast period can be attributed to digitalization and data analytics, risk management, flexibility and scalability, burgeoning investment in r&d, precision medicine and personalized therapies. Major trends in the forecast period include regenerative medicine, risk mitigation strategies, global collaborations, advanced technologies, technological integration.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report
Scope Of Biologics Contract Development Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Biologics Contract Development Market Overview
Market Drivers –
The rising prevalence of chronic diseases is expected to propel the biologics contract development market going forward. Chronic diseases refer to an illness that lasts for a year or longer that requires ongoing medical attention. The rise in chronic disease cases is increasing the demand for developing novel drugs, including biologics, thereby promoting the biologics contract development market. For instance, according to data published in April 2021 by the World Health Organization, a Switzerland-based health organization for international public health, 41 million people die every year due to chronic diseases globally, close to 71% of all deaths. Therefore, the rising prevalence of chronic diseases will drive the growth of the biologics contract development market.
Market Trends –
Technological advancements are gaining popularity in the biologics contract development market. Major companies in the biologics contract development market are integrating advanced technologies to sustain their position in the market. For instance, in January 2022, Lonza, a Switzerland-based contract manufacturing and development solutions company, launched bYlok technology platform to design and manufacture bispecific antibodies. It helps to solve the light-heavy chain mispairing issue with high yields, >95% accuracy, and the ability to maintain a mAb-like format. It can be accessed by pharma and biotech companies through a simple research license.
The biologics contract development market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Others Soruces
2) By Indication: Oncology, Immunological disorders, Cardiovascular disorders, Hematological disorders, Others Indications
3) By Product Service: Cell Line Development, Process Development, Others Product Services
Get an inside scoop of the biologics contract development market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp
Regional Insights –
North America was the largest region in the biologics contract development market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the biologics contract development market report are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., AbbVie Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Meridian Life Science Inc., Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Sartorius AG, Syngene International Limited, Vibalogics GmbH, Yposkesi, ZymoGenetics Inc.
Table of Contents
1. Executive Summary
2. Biologics Contract Development Market Report Structure
3. Biologics Contract Development Market Trends And Strategies
4. Biologics Contract Development Market – Macro Economic Scenario
5. Biologics Contract Development Market Size And Growth
…..
27. Biologics Contract Development Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
